

Challenges for Colorectal Cancer Screening in Europe

Bob Steele


University of Dundee and UK National Screening
Committee



JSD2020

How can we screen for colorectal cancer?

- Tests for blood in faeces
- Lower GI Endoscopy
- Novel tests ?



National program



Regional programs



Pilot study




Screening Tests Used


gFOBt




FIT



Flex-Sig



Colonoscopy



Invitation methods used

- Direct invitation from central agency using national registers
- Invitation by General Practitioner
- Self referral encouraged by central agency

UK National Screening Committee (NSC)

- Advises ministers and NHS
 - Starting, changing and stopping screening programmes
- Monitors new evidence
- Advises all four countries of the UK



Proving Screening Works

Population RCT



No screening
offered



Screening
Offered

(including those who
choose not to participate
and those developing
interval disease)

Compare numbers of deaths or adverse
outcomes from disease


Tests for Blood in Faeces

Guaiac Faecal Occult Blood (gFOBT) Trials


France



UK



Denmark



USA

Reduction in
death from
CRC of
16%



gFOBT vs FIT

- gFOBT
 - Based on Guaiac reaction
 - Not specific for haemoglobin
 - Inconvenient to do
- FIT
 - Immunological
 - Specific for human haemoglobin
 - Easy to do
 - Quantitative





Lower GI Endoscopy

What are the options?

- Colonoscopy
 - Very sensitive and 100% specific
 - Expensive
 - No RCTs (4 in progress world-wide)
- Flexible Sigmoidoscopy
 - Misses R-side disease
 - RCT evidence (UK, Italy, Norway, US)

UK Flexible Sigmoidoscopy Trial Mortality from CRC




Number at risk

| | | | | | | | |
|--------------|--------|--------|--------|--------|--------|--------|-------|
| Control | 112939 | 111321 | 109319 | 106907 | 104196 | 100597 | 18748 |
| Intervention | 57099 | 56300 | 55325 | 54164 | 52809 | 50972 | 9539 |

UK Flexible Sigmoidoscopy Trial

Incidence of CRC



Colorectal Screening in Scotland




- Everyone aged 50-74 invited centrally every two years
- Based on biennial gFOBT 2000-2017
- No flexible sigmoidoscopy
- Changed to FIT at 80 μ g/g in November 2017

Challenges for FIT


1. Uptake

2. Lowering the threshold

Uptake - gFOBt and FIT



Quantitative FIT – changing the threshold



| Faecal haemoglobin concentration (µg Hb/g faeces) | Positivity rate | CRC detected | CRC missed | % CRC missed | PPV |
|---|-----------------|--------------|------------|--------------|------|
| 80 | 3.1% | 711 | - | 5.2% | |
| 100 | 2.6% | 671 | 40 | 5.6% | 5.7% |
| 120 | 2.3% | 629 | 82 | 11.5% | 6.1% |
| 140 | 2.1% | 598 | 113 | 15.9% | 6.4% |
| 160 | 1.9% | 572 | 139 | 19.6% | 6.7% |
| 180 | 1.8% | 549 | 162 | 22.8% | 7.0% |
| 200 | 1.7% | 529 | 182 | 25.6% | 7.2% |

Challenges for Flexible Sigmoidoscopy

1. Uptake
2. Delivery
3. Quality

Problems with current flexible sigmoidoscopy programme in England

- Uptake poor (~40%)
- Yield of pathology low
- Delivery difficult
- Unpopular with endoscopists

Uptake

Why don't people accept CRC screening?

- Not invited
- Financial barriers
- Apathy / fatalism
- Fear
- Ignorance
- Disgust
- *Informed choice*

What can we do to increase uptake?


- Direct invitation
- Remove financial barriers
- Modifying the test
- Pre-notification
- Psychological Intervention
- National Publicity Campaigns
- Engaging with Primary Care

Delivery

UK NSC Recommendation

- Cost-effectiveness analysis
- FIT a threshold of 20 μg Hb/g faeces
- Age range 50 - 74

Positivity at Different Thresholds



Challenges for Europe

- Population coverage
 - Direct invitation of entire eligible population
 - Removal of financial barriers
- Delivery of the most effective test
 - Low FIT threshold
 - Investment in colonoscopy